AMA: FDA action on OTC naloxone will save people from overdoses

| 1 Min Read

Statement attributable to:
Patrice A. Harris, MD, MA
President-elect, chair of the AMA Opioid Task Force
American Medical Association

“The AMA applauds the FDA and Commissioner Gottlieb for today’s action to provide labeling that would allow for over-the-counter availability of naloxone, a move that will save people from opioid-related overdose. Naloxone has saved tens of thousands of lives, and the AMA continues to strongly urge physicians to co-prescribe naloxone to patients at risk of opioid-related overdose.

Full press statement available when you sign in

Sign in to the AMA website to get the full version of this press statement. 

AMA membership has its advantages

  • Be a part of the nation's largest physician organization
  • Play a role in shaping the future of health care
  • Enjoy exclusive perks and savings

Not a member? Become a member now.

 

FEATURED STORIES

Fingers point to activity trackers on smartwatches

Which specialties lead the way on using wearable data for care

| 7 Min Read
Stethoscope hanging on railing inside hospital

4 top factors that drive physicians to give up clinical practice

| 5 Min Read
Senior man using a phone at a clinic

CMS ACCESS Model launches in July: What doctors should know

| 5 Min Read
Chelsea Evans, DO, featured on "Health vs. Hype" AMA podcast

4 things to know about cold plunges and contrast therapy

| 5 Min Read